These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18721256)

  • 1. Comparison of pre- vs. postmeal administration of miglitol for 3 months in type 2 diabetic patients.
    Aoki K; Nakajima S; Nezu U; Shinoda K; Terauchi Y
    Diabetes Obes Metab; 2008 Sep; 10(10):970-2. PubMed ID: 18721256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
    Kishimoto M; Noda M
    Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients.
    Aoki K; Nakamura A; Ito S; Nezu U; Iwasaki T; Takahashi M; Kimura M; Terauchi Y
    Diabetes Res Clin Pract; 2007 Oct; 78(1):30-3. PubMed ID: 17493703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
    Imai C; Saito M; Mochizuki K; Fuchigami M; Goda T; Osonoi T
    Metabolism; 2014 Jun; 63(6):746-53. PubMed ID: 24559582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the α-glucosidase inhibitor miglitol on the glucose profile in Japanese type 2 diabetic patients receiving multiple daily insulin injections.
    Kato H; Ohta A; Kobayashi S; Ishii S; Sada Y; Kobayashi H; Ohmori S; Kondo A; Katabami T; Fuse J; Fukuda H; Nagai Y; Tanaka Y
    Endocr J; 2012; 59(4):345-52. PubMed ID: 22301938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
    Johnston PS; Feig PU; Coniff RF; Krol A; Kelley DE; Mooradian AD
    Diabetes Care; 1998 Mar; 21(3):416-22. PubMed ID: 9540025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
    Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
    J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
    Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA
    Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. alpha-Glucosidase inhibition by miglitol in NIDDM patients.
    Kingma PJ; Menheere PP; Sels JP; Nieuwenhuijzen Kruseman AC
    Diabetes Care; 1992 Apr; 15(4):478-83. PubMed ID: 1499461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of miglitol as an add-on to bolus insulin on postprandial glycemic excursions in type 2 diabetes patients assessed by continuous glucose monitoring.
    Matsuura K; Mori Y; Nakamura A; Yokoyama J; Utsunomiya K
    Diabetes Technol Ther; 2012 May; 14(5):423-9. PubMed ID: 22316114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus.
    Nagai E; Katsuno T; Miyagawa J; Konishi K; Miuchi M; Ochi F; Kusunoki Y; Tokuda M; Murai K; Hamaguchi T; Namba M
    Endocr J; 2011; 58(10):869-77. PubMed ID: 21869539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes.
    Chiasson JL; Naditch L;
    Diabetes Care; 2001 Jun; 24(6):989-94. PubMed ID: 11375358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
    Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
    Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
    Segal P; Feig PU; Schernthaner G; Ratzmann KP; Rybka J; Petzinna D; Berlin C
    Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease.
    Emoto T; Sawada T; Hashimoto M; Kageyama H; Terashita D; Mizoguchi T; Mizuguchi T; Motodi Y; Iwasaki M; Taira K; Okamoto H; Matsuo Y; Kim SK; Takarada A; Yokoyama M
    Am J Cardiol; 2012 Jan; 109(1):42-6. PubMed ID: 21944671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol.
    Uzu T; Yokoyama H; Itoh H; Koya D; Nakagawa A; Nishizawa M; Maegawa H; Yokomaku Y; Araki S; Abiko A; Haneda M
    Clin Exp Nephrol; 2011 Feb; 15(1):58-63. PubMed ID: 20824296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients.
    Pagano G; Marena S; Corgiat-Mansin L; Cravero F; Giorda C; Bozza M; Rossi CM
    Diabete Metab; 1995 Jun; 21(3):162-7. PubMed ID: 7556806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
    Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
    Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients.
    Johnston PS; Coniff RF; Hoogwerf BJ; Santiago JV; Pi-Sunyer FX; Krol A
    Diabetes Care; 1994 Jan; 17(1):20-9. PubMed ID: 8112185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus.
    Tatsumi F; Hashiramoto M; Hirukawa H; Kimura T; Shimoda M; Tawaramoto K; Kanda-Kimura Y; Anno T; Kawasaki F; Mune T; Matsuki M; Kaku K
    Diabetes Res Clin Pract; 2013 Jul; 101(1):35-44. PubMed ID: 23711593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.